Alterity Therapeutics Ltd ADR (ATHE)

$3.48 -0.06 (-1.68%)
Market Cap 31.39M
Revenue (ttm) 0.00
Net Income (ttm) -12.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 8,000
Avg Vol 24,494
Day's Range N/A - N/A
Shares Out 8.87M
Stochastic %K 83%
Beta 0.71
Analysts Strong Sell
Price Target $11.00

Latest News on ATHE

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Apr 10, 2025, 7:35 AM EDT - 15 days ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Mar 27, 2025, 7:25 AM EDT - 4 weeks ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Alterity Therapeutics Raises A$40.0 million in Placement

Feb 10, 2025, 7:25 AM EST - 2 months ago

Alterity Therapeutics Raises A$40.0 million in Placement

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 30, 2025, 7:35 AM EST - 3 months ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 24, 2025, 7:35 AM EST - 3 months ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Jan 9, 2025, 7:25 AM EST - 3 months ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Dec 4, 2024, 7:35 AM EST - 5 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 19, 2024, 7:25 AM EST - 5 months ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 12, 2024, 7:35 AM EST - 5 months ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Nov 6, 2024, 7:35 AM EST - 6 months ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 31, 2024, 7:35 AM EDT - 6 months ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 14, 2024, 7:35 AM EDT - 6 months ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 11, 2024, 7:35 AM EDT - 7 months ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Oct 2, 2024, 7:35 AM EDT - 7 months ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 30, 2024, 7:35 AM EDT - 7 months ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2024, 7:35 AM EDT - 7 months ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 31, 2024, 7:35 AM EDT - 9 months ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Alterity Therapeutics to Present at MST Financial Webinar

Jul 24, 2024, 7:35 AM EDT - 9 months ago

Alterity Therapeutics to Present at MST Financial Webinar

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:35 AM EDT - 10 months ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 10 months ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Jun 12, 2024, 7:22 PM EDT - 11 months ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 29, 2024, 7:21 PM EDT - 11 months ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

May 8, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 29, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Apr 10, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Mar 26, 2024, 10:25 AM EDT - 1 year ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 20, 2024, 10:25 AM EST - 1 year ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Feb 6, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Jan 29, 2024, 7:24 AM EST - 1 year ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 21, 2023, 12:30 AM EST - 1 year ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Dec 4, 2023, 4:35 PM EST - 1 year ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Dec 4, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Nov 27, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

Nov 16, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Nov 8, 2023, 7:25 AM EST - 1 year ago

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Oct 30, 2023, 7:25 AM EDT - 1 year ago

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Aug 31, 2023, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer's

Aug 23, 2023, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer's

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement Disorders

Aug 22, 2023, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

Aug 15, 2023, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

Jul 31, 2023, 7:52 AM EDT - 1 year ago

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

Jul 26, 2023, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

Jun 21, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

May 30, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023

May 19, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023

Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

May 10, 2023, 7:25 AM EDT - 2 years ago

Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

May 10, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

Apr 26, 2023, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology